Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 48

1.

Phase II Study to Evaluate the Efficacy and Safety of Rilotumumab and Bevacizumab in Subjects with Recurrent Malignant Glioma.

Affronti ML, Jackman JG, McSherry F, Herndon JE 2nd, Massey EC Jr, Lipp E, Desjardins A, Friedman HS, Vlahovic G, Vredenburgh J, Peters KB.

Oncologist. 2018 Aug;23(8):889-e98. doi: 10.1634/theoncologist.2018-0149. Epub 2018 Apr 17.

PMID:
29666296
2.

The efficacy and safety of targeted therapy with or without chemotherapy in advanced gastric cancer treatment: a network meta-analysis of well-designed randomized controlled trials.

Zhao TT, Xu H, Xu HM, Wang ZN, Xu YY, Song YX, Yin SC, Liu XY, Miao ZF.

Gastric Cancer. 2018 May;21(3):361-371. doi: 10.1007/s10120-018-0813-2. Epub 2018 Feb 17. Review.

PMID:
29455269
3.

A Phase 1/1b tolerability study of rilotumumab alone or in combination with cisplatin and capecitabine in Japanese patients with gastric cancer.

Doi T, Yamaguchi K, Komatsu Y, Muro K, Nishina T, Nakajima TE, Tang R, Yang H, Zhang Y, Jung AS, Ang A, Yasui H.

Jpn J Clin Oncol. 2017 Nov 1;47(11):1002-1009. doi: 10.1093/jjco/hyx114.

PMID:
28973403
4.

Rilotumumab plus epirubicin, cisplatin, and capecitabine as first-line therapy in advanced MET-positive gastric or gastro-oesophageal junction cancer (RILOMET-1): a randomised, double-blind, placebo-controlled, phase 3 trial.

Catenacci DVT, Tebbutt NC, Davidenko I, Murad AM, Al-Batran SE, Ilson DH, Tjulandin S, Gotovkin E, Karaszewska B, Bondarenko I, Tejani MA, Udrea AA, Tehfe M, De Vita F, Turkington C, Tang R, Ang A, Zhang Y, Hoang T, Sidhu R, Cunningham D.

Lancet Oncol. 2017 Nov;18(11):1467-1482. doi: 10.1016/S1470-2045(17)30566-1. Epub 2017 Sep 25.

PMID:
28958504
5.

Evaluation of short-term effectiveness of eight targeted agents combined with chemotherapy for treating esophageal-gastric junction adenocarcinoma: A network meta-analysis.

He YM, Yu C, Li WB, Li ZP, Xu N.

J Cell Biochem. 2018 Jan;119(1):1183-1192. doi: 10.1002/jcb.26288. Epub 2017 Oct 5.

PMID:
28708307
6.

A Randomized, Placebo-Controlled, Phase 1b/2 Study of Rilotumumab or Ganitumab in Combination With Platinum-Based Chemotherapy as First-Line Treatment for Extensive-Stage Small-Cell Lung Cancer.

Glisson B, Besse B, Dols MC, Dubey S, Schupp M, Jain R, Jiang Y, Menon H, Nackaerts K, Orlov S, Paz-Ares L, Ramlau R, Tang R, Zhang Y, Zhu M.

Clin Lung Cancer. 2017 Nov;18(6):615-625.e8. doi: 10.1016/j.cllc.2017.05.007. Epub 2017 May 10.

PMID:
28601388
7.

Phase 1/2 study of rilotumumab (AMG 102), a hepatocyte growth factor inhibitor, and erlotinib in patients with advanced non-small cell lung cancer.

Tarhini AA, Rafique I, Floros T, Tran P, Gooding WE, Villaruz LC, Burns TF, Friedland DM, Petro DP, Farooqui M, Gomez-Garcia J, Gaither-Davis A, Dacic S, Argiris A, Socinski MA, Stabile LP, Siegfried JM.

Cancer. 2017 Aug 1;123(15):2936-2944. doi: 10.1002/cncr.30717. Epub 2017 May 4.

8.

89Zr-DFO-AMG102 Immuno-PET to Determine Local Hepatocyte Growth Factor Protein Levels in Tumors for Enhanced Patient Selection.

Price EW, Carnazza KE, Carlin SD, Cho A, Edwards KJ, Sevak KK, Glaser JM, de Stanchina E, Janjigian YY, Lewis JS.

J Nucl Med. 2017 Sep;58(9):1386-1394. doi: 10.2967/jnumed.116.187310. Epub 2017 Mar 9.

9.

A Phase II Randomized Trial (GO27827) of First-Line FOLFOX Plus Bevacizumab with or Without the MET Inhibitor Onartuzumab in Patients with Metastatic Colorectal Cancer.

Bendell JC, Hochster H, Hart LL, Firdaus I, Mace JR, McFarlane JJ, Kozloff M, Catenacci D, Hsu JJ, Hack SP, Shames DS, Phan SC, Koeppen H, Cohn AL.

Oncologist. 2017 Mar;22(3):264-271. doi: 10.1634/theoncologist.2016-0223. Epub 2017 Feb 16.

10.

Assessment of pharmacokinetic interaction between rilotumumab and epirubicin, cisplatin and capecitabine (ECX) in a Phase 3 study in gastric cancer.

Zhang Y, Kuchimanchi M, Zhu M, Doshi S, Hoang T, Kasichayanula S.

Br J Clin Pharmacol. 2017 May;83(5):1048-1055. doi: 10.1111/bcp.13179. Epub 2016 Dec 13.

11.

Targeted therapies for advanced and metastatic adenocarcinoma of the gastroesophageal junction: is there something new?

Pasini F, Fraccon AP, Modena Y, Bencivenga M, Giacopuzzi S, La Russa F, Gusella M, de Manzoni G.

Gastric Cancer. 2017 Jan;20(1):31-42. doi: 10.1007/s10120-016-0626-0. Epub 2016 Aug 27. Review.

PMID:
27568322
12.

Biomarker development in MET-targeted therapy.

Zhang Y, Du Z, Zhang M.

Oncotarget. 2016 Jun 14;7(24):37370-37389. doi: 10.18632/oncotarget.8276. Review.

13.

Monoclonal antibodies for treating gastric cancer: promises and pitfalls.

Sibertin-Blanc C, Ciccolini J, Norguet E, Lacarelle B, Dahan L, Seitz JF.

Expert Opin Biol Ther. 2016 Jun;16(6):759-69. doi: 10.1517/14712598.2016.1164137. Epub 2016 Mar 25. Review.

PMID:
26971395
14.

Hepatocyte growth factor inhibition: a novel therapeutic approach in pancreatic cancer.

Pothula SP, Xu Z, Goldstein D, Biankin AV, Pirola RC, Wilson JS, Apte MV.

Br J Cancer. 2016 Feb 2;114(3):269-80. doi: 10.1038/bjc.2015.478. Epub 2016 Jan 14.

15.

Incomplete target neutralization by the anti-cancer antibody rilotumumab.

Greenall SA, Adams TE, Johns TG.

MAbs. 2016;8(2):246-52. doi: 10.1080/19420862.2015.1122149.

16.

Pharmacokinetics and pharmacodynamics of rilotumumab: a decade of experience in preclinical and clinical cancer research.

Zhang Y, Doshi S, Zhu M.

Br J Clin Pharmacol. 2015 Nov;80(5):957-64. doi: 10.1111/bcp.12663. Epub 2015 May 26. Review.

17.

Rilotumumab exposure-response relationship in patients with advanced or metastatic gastric cancer.

Doshi S, Gisleskog PO, Zhang Y, Zhu M, Oliner KS, Loh E, Perez Ruixo JJ.

Clin Cancer Res. 2015 Jun 1;21(11):2453-61. doi: 10.1158/1078-0432.CCR-14-1661. Epub 2015 Feb 24.

18.

Exposure-response analysis of rilotumumab in gastric cancer: the role of tumour MET expression.

Zhu M, Tang R, Doshi S, Oliner KS, Dubey S, Jiang Y, Donehower RC, Iveson T, Loh EY, Zhang Y.

Br J Cancer. 2015 Feb 3;112(3):429-37. doi: 10.1038/bjc.2014.649. Epub 2015 Jan 13.

19.

Potential role of rilotumumab in the treatment of gastric cancer.

Waddell T, Moorcraft SY, Cunningham D.

Immunotherapy. 2014;6(12):1243-53. doi: 10.2217/imt.14.91. Review.

PMID:
25524381
20.

C-MET inhibitors in the treatment of lung cancer.

Goździk-Spychalska J, Szyszka-Barth K, Spychalski L, Ramlau K, Wójtowicz J, Batura-Gabryel H, Ramlau R.

Curr Treat Options Oncol. 2014 Dec;15(4):670-82. doi: 10.1007/s11864-014-0313-5. Review.

PMID:
25266653

Supplemental Content

Loading ...
Support Center